ALTEROLA BIOTECH INC.

CIK:0001442999|SEC Filings

UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
REVENUES	$ 0	$ 0	$ 0	$ 0
OPERATING EXPENSES:
Accounting and audit fees	91,548	23,162	213,978	72,100
Professional fees	13,748	1,895	16,049	7,185
Research and Development	16,964	0	36,099	0
Legal Fees	96,060	0	168,841	12,899
Directors fees and expenses	0	25,000	0	196,000
Consulting Fees	234,342	15,937	613,400	333,678
Salaries and wages	546	33,519	44,209	69,458
General and administrative - other	24,023	23,644	67,477	25,404
TOTAL OPERATING EXPENSES	477,231	123,157	1,160,053	716,724
LOSS FROM OPERATIONS	(477,231)	(123,157)	(1,160,053)	(716,724)
OTHER INCOME (EXPENSES):
Gain (loss) on conversion of note	0	0	0	(138,163)
Interest expense	337,297	337,297	0	0
Foreign currency exchange differences	15,235	0	43,310	0
TOTAL OTHER INCOME (EXPENSE)	(321,962)	0	(293,887)	(138,163)
LOSS BEFORE INCOME TAXES	(799,193)	(123,157)	(1,453,940)	(854,887)
PROVISION FOR INCOME TAXES	0	0	0	0
NET LOSS	(799,193)	(123,157)	(1,453,940)	(854,887)
Net Loss of subsidiaries attributable to noncontrolling interest	(107,362)	0	(196,281)	0
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (691,831)	$ (123,157)	$ (1,257,659)	$ (854,887)
NET LOSS PER SHARE: Basic and diluted	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: Basic and diluted	1,467,475,253	800,109,341	1,448,712,132	801,824,998
COMPREHENSIVE LOSS: Net loss	$ (799,193)	$ (123,157)	$ (1,453,940)	$ (854,887)
Other comprehensive loss:
Unrealized foreign currency translation gain	(4,190)	(26,214)	(4,190)	(26,214)
Comprehensive loss	$ (803,383)	$ (149,371)	$ (1,458,130)	$ (881,101)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	6 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,453,940)	$ (854,887)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Shares issued for services	306,635	321,760
Shares issued for services - directors	0	180,000
Shares issued for warrants	0	13,500
Changes in: operating assets and liabilities:
Inventories	(60)	0
VAT Receivable	0	37,953
Deferred tax asset	0	2,224
Accounts Payable	(19,902)	110,319
Accrued liabilities	99,538	(8,494)
Net cash used in operating activities	(1,067,729)	(197,625)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of Alinova	0	35,000
Acquisition of intangible assets	(60,000)	0
Net cash (used in) provided by Investing Activities	(60,000)	35,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from notes payable	2,493,935	0
Loans receivable issued	(1,063,235)	0
Payment of Deferred offering costs	(157,045)	0
Proceeds from sale of common stock	200	0
Purchase of common shares for cash	0	(44,064)
Treasury shares received	0	(170,709)
Proceeds from related party loans	49,014	290,303
Net cash provided by financing activities	1,322,869	75,530
NET INCREASE (DECREASE) IN CASH	195,140	(87,095)
Effect of exchange rate adjustments on cash	(115,074)	87,307
CASH, beginning of period	2,654	8,890
CASH, end of period	82,720	9,102
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	0	0
NON-CASH INVESTING AND FINANCING INFORMATION:
Increase in equity and debt discount	$ 340,535	$ 0

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Mar. 31, 2024
Current assets:
Cash in bank	$ 82,720	$ 2,654
Loans receivable	1,063,235	0
Inventories	1,069	1,009
Total current assets	1,147,024	3,663
Long-term assets:
Intangible assets	60,000	0
Deferred offering costs	157,045	0
Total Assets	1,364,069	3,663
Current liabilities:
Notes payable, net	1,839,731	0
Convertible note payable	313,669	0
Accounts payable	805,308	825,210
Accrued liabilities	461,989	362,451
Loans payable, related parties	194,617	145,603
Total current liabilities	3,615,314	1,333,264
Total liabilities	3,615,314	1,333,264
Commitments and Contingencies	0	0
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.001 par value. 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 1,467,475,449 and 1,382,662,949 shares issued and outstanding, respectively	1,467,485	1,382,663
Additional paid in capital	10,226,499	9,663,951
Accumulated deficit	(13,673,734)	(12,416,075)
Accumulated other comprehensive income (loss)	(75,214)	39,860
Total stockholders' deficit attributable to owners of the parent	(2,054,964)	(1,329,601)
Non-controlling interest	(196,281)	0
Total stockholder's deficit	(2,251,245)	(1,329,601)
Total liabilities and stockholders' deficit	$ 1,364,069	$ 3,663